Business
c.£1.5 million Contract Extension
IXICO plc has announced a contract extension worth approximately £1.5 million in additional revenue over the next three years, stemming from the continued progress of a Phase 2 clinical trial in Huntington's Disease with a major international pharmaceutical company. This extension, secured within two months of other new revenue totaling over £2.7 million from two existing clients, highlights the value of IXICO's AI-driven platform and neuroscience expertise in advancing drug development for neurological disorders. Disclaimer*
About this update from Ixico Plc
[{"type":"text","content":"\n\nIXICO plc\n(\"IXICO\", the \"Company\" or the \"Group\")\n \nc.£1.5 million contract extension on global Phase 2 clinical trial \n \n \n12 February 2026, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced the extension of an existing contract with one of the world's leading international pharmaceutical companies following the continued progress of a Phase 2 clinical trial in Huntington's Disease.\n \nThe contract extension is worth an additional c.£1.5 million in revenues to IXICO over the next three years. \n \nBram Goorden, CEO of IXICO, commented: \"Thanks to this contract extension IXICO has secured over £2.7m in new revenues with 2 existing clients in the last 2 months. This is another example of how IXICO's compelling IXI™ technology platform and neurological disease expertise consistently deliver gold standard outcomes for biopharma customers as they advance drug development in such a devastating neurological disease.\"\n \nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\n \nEnds\n \nFor further information please contact:\n \n\n\n\n\nIXICO plc\n\n\n+44 (0) 20 3763 7499\n\n\n\n\nGrant Nash, Chief Financial Officer\nJames Chandler, Chief Business Officer\n\n\n\n\n\n\n\n \nCavendish Capital Markets Limited\n(Nominated Adviser and Sole Broker)\n\n\n \n+44 (0) 20 7220 0500\n\n\n\n\nGiles Balleny, Isaac Hooper (Corporate Finance)\nNigel Birks (Healthcare Specialist Sales)\nHarriet Ward (Corporate Broking)\nMichael F Johnson (Sales)\n\n\n\n\n\n\n\n \n \nAbout IXICO www.IXICO.com\nIXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitori...